Tiziana Life Sciences gets funding for a new ALS treatment trial from the ALS Association.
Tiziana Life Sciences has received funding from the ALS Association to conduct a clinical trial for a new treatment for ALS, or Lou Gehrig's disease. The trial will test intranasal foralumab, a therapy aimed at reducing neuroinflammation, in 20 patients. The grant comes from the Hoffman ALS Clinical Trial Awards Program, which supports early-stage trials of potential new ALS treatments.
November 19, 2024
3 Articles